Understanding Limitations in At-work Productivity in Patients with Active Ankylosing Spondylitis: The Role of Work-related Contextual Factors

REFERENCES

1. 1.↵
   1. Braun J,
   2. Sieper J

   . Ankylosing spondylitis. Lancet 2007; 369:1379–90.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Kiltz U,
   2. van der Heijde D

   . Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol 2009;27 Suppl 55:S108–11.

   OpenUrlPubMed
3. 3.↵
   1. Bergström G,
   2. Bodin L,
   3. Hagberg J,
   4. Aronsson G,
   5. Josephson M

   . Sickness presenteeism today, sickness absenteeism tomorrow? A prospective study on sickness presenteeism and future sickness absenteeism. J Occup Environ Med 2009;51:629–38.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Mau W,
   2. Listing J,
   3. Huscher D,
   4. Zeidler H,
   5. Zink A

   . Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32:721–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Marengo MF,
   2. Schneeberger EE,
   3. Citera G,
   4. Cocco JA

   . Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 2008;14:273–7.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Boonen A,
   2. Chorus A,
   3. Miedema H,
   4. van der Heijde D,
   5. Landewé R,
   6. Schouten H,
   7. et al.

   Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. van der Heijde D,
   2. Han C,
   3. DeVlam K,
   4. Burmester G,
   5. van den Bosch F,
   6. Williamson P,
   7. et al.

   Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569–74.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Haibel H,
   2. Song IH,
   3. Rudwaleit M,
   4. Listing J,
   5. Hildemann S,
   6. Sieper J

   . Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol 2008;26:247–52.

   OpenUrlPubMed
9. 9.↵
   1. Keat AC,
   2. Gaffney K,
   3. Gilbert AK,
   4. Harris C,
   5. Leeder J

   . Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology 2008;47:481–3.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Kristensen LE,
    2. Petersson IF,
    3. Geborek P,
    4. Joud A,
    5. Saxne T,
    6. Jacobsson LT,
    7. et al.

    Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology 2012;51:243–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Listing J,
    2. Brandt J,
    3. Rudwaleit M,
    4. Zink A,
    5. Sieper J,
    6. Braun J

    . Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670–2.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Maksymowych WP,
    2. Gooch KL,
    3. Wong RL,
    4. Kupper H,
    5. van der Heijde D

    . Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010;37:385–92.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Boonen A,
    2. van der Heijde D,
    3. Landewé R,
    4. Spoorenberg A,
    5. Schouten H,
    6. Rutten-van Molken M,
    7. et al.

    Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429–37.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Boonen A,
    2. de Vet H,
    3. van der Heijde D,
    4. van der Linden S

    . Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 2001;28:1056–62.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Boonen A,
    2. Brinkhuizen T,
    3. Landewe R,
    4. van der Heijde D,
    5. Severens JL

    . Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010;69:1123–8.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    World Health Organization. International classification of functioning, disability and health (ICF). [Internet. Accessed September 24, 2014.] Available from: www.who.int/classifications/icf/en
17. 17.↵
    1. van Echteld I,
    2. Cieza A,
    3. Boonen A,
    4. Stucki G,
    5. Zochling J,
    6. Braun J,
    7. et al.

    Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 2006;33:2475–83.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Boers M,
    2. Idzerda L,
    3. Kirwan JR,
    4. Beaton D,
    5. Escorpizo R,
    6. Boonen A,
    7. et al.

    Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol 2014;41:978–85.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Tang K,
    2. Escorpizo R,
    3. Beaton DE,
    4. Bombardier C,
    5. Lacaille D,
    6. Zhang W,
    7. et al.

    Measuring the impact of arthritis on worker productivity: perspectives, methodologic issues, and contextual factors. J Rheumatol 2011;38:1776–90.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A

    . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.

    OpenUrlPubMed
21. 21.↵
    1. Reilly MC,
    2. Gooch KL,
    3. Wong RL,
    4. Kupper H,
    5. van der Heijde D

    . Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology 2010;49:812–9.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Koopmanschap MA

    . PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoecon Outcomes Res 2005;5:23–8.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Calin A,
    2. Jones SD,
    3. Garrett SL,
    4. Kennedy LG

    . Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol 1995;34:793–4.

    OpenUrlFREE Full Text
24. 24.↵
    1. van der Heijde D,
    2. Lie E,
    3. Kvien TK,
    4. Sieper J,
    5. Van den Bosch F,
    6. Listing J,
    7. et al.

    ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–8.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Jenkinson TR,
    2. Mallorie PA,
    3. Whitelock HC,
    4. Kennedy LG,
    5. Garrett SL,
    6. Calin A

    . Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.

    OpenUrlPubMed
26. 26.↵
    1. van der Heijde D,
    2. Landewé R,
    3. Feldtkeller E

    . Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489–93.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. van der Heijde D,
    2. Deodhar A,
    3. Inman RD,
    4. Braun J,
    5. Hsu B,
    6. Mack M

    . Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. Arthritis Care Res 2012;64:1919–22.

    OpenUrlCrossRef
28. 28.↵
    1. Jones SD,
    2. Steiner A,
    3. Garrett SL,
    4. Calin A

    . The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66–71.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Verstappen SM,
    2. Watson KD,
    3. Lunt M,
    4. McGrother K,
    5. Symmons DP,
    6. Hyrich KL

    . Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:1570–7.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Healey EL,
    2. Haywood KL,
    3. Jordan KP,
    4. Garratt A,
    5. Packham JC

    . Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol 2011;40:34–40.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Ariza-Ariza R,
    2. Hernandez-Cruz B,
    3. Collantes E,
    4. Batlle E,
    5. Fernandez-Sueiro JL,
    6. Gratacos J,
    7. et al.

    Work disability in patients with ankylosing spondylitis. J Rheumatol 2009;36:2512–6.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Bakland G,
    2. Gran JT,
    3. Becker-Merok A,
    4. Nordvag BY,
    5. Nossent JC

    . Work disability in patients with ankylosing spondylitis in Norway. J Rheumatol 2011;38:479–84.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Barlow JH,
    2. Wright CC,
    3. Williams B,
    4. Keat A

    . Work disability among people with ankylosing spondylitis. Arthritis Rheum 2001; 45:424–9.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Cakar E,
    2. Taskaynatan MA,
    3. Dincer U,
    4. Kiralp MZ,
    5. Durmus O,
    6. Ozgul A

    . Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 2009;28:1309–14.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Chorus AM,
    2. Boonen A,
    3. Miedema HS,
    4. van der Linden S

    . Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis 2002;61:693–9.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Gran JT,
    2. Skomsvoll JF

    . The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766–71.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Ramos-Remus C,
    2. Hernandez-Rios G,
    3. Duran-Barragan S,
    4. Sanchez-Ortiz A,
    5. Aceves-Avila FJ,
    6. Castillo-Ortiz JD,
    7. et al.

    Fifteen-year trends of long-term disability and sick leaves in ankylosing spondylitis. Clin Rheumatol 2011;30:361–7.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Rkain H,
    2. Allali F,
    3. Bentalha A,
    4. Lazrak N,
    5. Abouqal R,
    6. Hajjaj-Hassouni N

    . Socioeconomic impact of ankylosing spondylitis in Morocco. Clin Rheumatol 2007;26:2081–8.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Ward MM,
    2. Kuzis S

    . Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001;28:315–21.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Grazio S,
    2. Jajić Z,
    3. Nemcić T,
    4. Jajić I

    . [Work capacity evaluation in patients with ankylosing spondylitis]. [Article in Croatian] Reumatizam 1997;45:1–5.

    OpenUrlPubMed
42. 42.↵
    1. Guillemin F,
    2. Briancon S,
    3. Pourel J,
    4. Gaucher A

    . Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum 1990;33:1001–6.

    OpenUrlCrossRefPubMed